by Kristan Bahten, Sr. Product Marketing Manager, Thermo Fisher Scientific
It’s little surprise that proteomics is a fast-expanding sector. As, perhaps, the most valuable of the “omics,” it characterizes the expression of the genome, and provides insight into every protein modification and complex interaction. This usefulness is backed up in the finances too. Proteomics is on track to be worth $50 billion by 2027 with a projected annual growth rate of 12.2% from 2020 to 2027.1
Proteomics is not just a tool for the future, it is already used to diagnose disease, evaluate its progression and assess the efficacy of drug discoveries, and its usefulness only increases as we move towards the era of personalized medicine. Yet, despite the clear benefits and growth in this important field, proteomics is still relying on highly manual, time-consuming and costly processes within the sample preparation stages. These cumbersome steps are creating a bottleneck in analytical laboratories, diverting highly skilled scientists to carry out repetitive tasks, and increasing error and failure rates in the analysis stages.
Read more on Labcompare.